Krystal Biotech, Inc. (KRYS)
NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
As of 09:37AM EDT. Market open.
| Previous close | 161.10 |
| Open | 144.43 |
| Bid | 106.56 x 200 |
| Ask | 186.04 x 200 |
| Day's range | 144.00 - 152.15 |
| 52-week range | 83.38 - 189.97 |
| Volume | |
| Avg. volume | 389,980 |
| Market cap | 4.278B |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | 384.69 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Krystal Biotech Inc (KRYS) Surpasses Revenue Estimates in Q1 2024
Details on Financial Performance and Strategic Progress
- Zacks
Why Krystal Biotech (KRYS) Might Surprise This Earnings Season
Krystal Biotech (KRYS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Zacks
Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
© 2024 Yahoo. All rights reserved.